The 1996 costs of patients with serious psychiatric disorders and/or HIV/AIDS are much higher than previously thought

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.585, 2009-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Indirect Costs in Ambulatory Patients with HIV/AIDS in Spain: A Pilot Study

By Oliva J.   Roa C.  

PharmacoEconomics, Vol. 21, Iss. 15, 2003-01 ,pp. : 1113-1121

Adis International

Access to resources Recommend Favorite

Economic Costs to Business of the HIV/AIDS Epidemic

By Gordon G. Liu   Jeff J. Guo   Scott R. Smith  

PharmacoEconomics, Vol. 22, Iss. 18, 2004-01 ,pp. : 1181-1194

Adis International

Access to resources Recommend Favorite

Modelling outcomes and costs of HIV/AIDS therapy

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 360, 2002-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Indirect costs of HIV/AIDS substantial in Spain

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 433, 2003-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

HIV/AIDS Patients Display Lower Relative Bioavailability of Efavirenz than Healthy Subjects

By Mukonzo Jackson K.   Nanzigu Sarah   Rekić Dinko  

Clinical Pharmacokinetics, Vol. 50, Iss. 8, 2011-08 ,pp. : 531-540

Adis International

Access to resources Recommend Favorite